Lv1
20 积分 2025-06-18 加入
First‐line envafolimab plus recombinant human‐endostatin in advanced non–small cell lung cancer with PD‐L1 tumor proportion score ≥1% (Endouble): A multicenter, prospective, single‐arm, phase 2 trial
4小时前
待确认
Drastic Response of Re-challenge of EGFR-TKIs Immediately After Nivolumab Therapy in EGFR-TKI–Resistant Patients
8个月前
已完结
Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis
8个月前
已完结
皖公网安备34019202002308
